Nordic Life Science 1
Per Walday CEO of EXACT Therapeutics CHRISTOPHE B
OURDON JOINS LEO Pharma from Orphazyme where he held the position as CEO since April 2021. His previous roles include Senior Vice President, General Manager, U.S. Oncology Business, at Amgen Inc. where he also led commercialization planning of drugs on the global market. Prior to Amgen, he was Senior Vice President of Europe, Middle East, Africa, and Canada at Alexion. Christophe Bourdon holds an MBA from IMD Business School (Switzerland) and a BA from ISG (France). “I am excited to join LEO Pharma and bring my competence and experience into play as LEO Pharma goes through the next phases of its transformation. The company’s strong heritage appeals to me as well as the unique profile in medical dermatology. LEO Pharma has a huge potential for growth and for making a difference for people who need more treatment options for their skin conditions,” says Bourdon. 20 NORDICLIFESCIENCE.ORG ANDERS TULLGREN WILL succeed Sveinung Hole as Chairman of the Board of Directors. He has over 35 years of global experience in both large pharmaceutical and small/ mid-size biotech environments, with senior leadership roles in the US, Germany, France, the UK, and the Nordic region. He spent over 20 years at Bristol Myers Squibb, most recently as President, Intercontinental Region at the firm. Tullgren is an experienced non-executive director with current Board and Chair positions at Branding Science, Xbrane Biopharma, Farmalisto and Dizlin Pharmaceuticals. He holds an MSc in Pharmaceutical Studies from Uppsala University and a Diploma in Marketing & Business Administration from MIS. “It is an honor to have the opportunity to take on the role of Chairman and to work within an incredible company and alongside a strong leadership team. I look forward to supporting BerGenBio as it advances the progression of its lead candidate,” says Tullgren. MARTIN NICKLASSON HOLDS a Ph.D. in Pharmaceutical Sciences from Uppsala University and is a certified pharmacist of Sweden. He has a broad managerial background in the fields of e.g.marketing and R&D. From 2007 to the end of 2010, Nicklasson served as President and CEO of Biovitrum and Sobi. From 1999 to 2007 he held various Executive Vice President positions at AstraZeneca Plc. and was a member of the Senior Executive Committee. Martin Nicklasson has held and holds various chairman and board member positions in biotech and biopharma companies. Currently he serves as Chairman of Zealand Pharma and he is a board member of Basilea Pharmaceutica. “I am very much looking forward to assist in continuing Nykode Therapeutics’ journey of internationalization as well as to further develop Nykode Therapeutics’ position as a leading next generation immunotherapy platform company,” says Nicklasson PER WALDAY HAS experience from research to commercialization of therapeutics and medical devices globally, including drug-device combination within the field of oncology. As CEO of PCI Biotech he progressed the platform technology into a pipeline of assets including in late stage clinical programs through FDA and EMA regulatory paths. Prior to this, he spent almost two decades with Nycomed Imaging and GE Healthcare based in Norway where, as Global Head Project Management, he was responsible for all development programs of new pharmaceutical products. These included R&D efforts within the field of ultrasound and microbubbles, which paved the way for what would become years later EXACT-Tx’s Acoustic Cluster Therapy. “I aim to further maximize the value of the innovative ACT platform for ultrasound mediated drug enhancement and accelerate our journey towards becoming a leading precision health company,” says Walday. PHOTO PETER PHILLIPS